Nasopharyngeal carcinoma and therapeutic management: The place of chemotherapy

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Guigay, J ^a   Temam, S ^a   Bourhis, J ^a   Pignon, J P ^a   Armand, J P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CETUXIMAB; CISPLATIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; META ANALYSIS; METASTASIS POTENTIAL; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; HUMANS; NASOPHARYNGEAL NEOPLASMS;

EID: 33749598743     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl278     Document Type: Article

References (38)

1. Spano JP, Busson P, Atlan D et al. Nasopharyngeal carcinomas: An update. Eur J Cancer 2003; 39: 2121-2135.
2. Licitra L, Bernier J, Cvitkovic E et al. Cancer of the nasopharynx. Crit Rev Oncol/Hematol 2003; 45: 199-214.
3. Sanguineti G, Bossi P, Pou A et al. Timing of chemotherapy and patient selection for locally advanced nasopharyngeal carcinoma. Clin Oncol 2003; 15: 451-460.
4. Chua DTT, Sham JST, Kwong DLW et al. Treatment outcome after radiotherapy alone for patients with stage I - II nasopharyngeal carcinoma. Cancer 2003; 98: 74-80.
5. Leung S, Chan ATC, Zee B et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of post therapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 2003; 98: 288-291.
6. Chan ATC, Lo YMD, Zee B et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94: 1614-1619.
7. Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma. Am J Clin Oncol 2002; 25: 219-223.
8. Langendijk JA, Leemans R, Buter J et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A meta-analysis of the published literature. J Clin Oncol 2004; 22: 4604-4612.
9. Ma BBY, Chan ATC. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 2005; 103: 22-31.
10. Baujat B, Audry H, Jean Bourhis J et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006; 64: 47-56.
11. Emami B, Sethi A, Petruzzelli G. Influence of MRI on target volume delineation and IMRT planning in nasopharyngeal carcinoma. Int J Radiation Oncology Biol Phys 2003; 57: 481-488.
12. Talmi YP, Horowitz Z, Bedrin L et al. Quality of life of nasopharyngeal carcinoma patients. Cancer 2002; 94: 1012-1017.
13. Rossi A, Molinari R, Boracchi P et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in loco-regional nasopharyngeal cancer: Results of 4-year multicenter randomized study. J Clin Oncol 1988; 6: 1401-1410.
14. Chan ATC, Teo PML, Leung TW et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995; 33: 569-577.
15. Al-Sarraf M, LeBlanc M, Shanker PG et al. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. J Clin Oncol 1998; 16: 1310-1317.
16. Chi KH, Chang Y, Guo W et al. A phase III study of adjuvant chemotherapy in advanced stage nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002; 52: 1238-1244.
17. Faivre S, Janot F, Armand JP. Optimal management of nasopharyngeal carcinoma. Curr Opin Oncol 2004; 16: 231-235.
18. Gvitkovic E, Eschwege F, Rahal M et al. Preliminary results of trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in Stage IV (≥N2, M0) undifferentiated nasopharyngeal carcinoma: A positive effect on progression free survival. Int J Radiat Oncol Biol Phys 1996; 35: 463-469.
19. Chua DT, Sham JS, Choy D et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer 1998; 83: 2270-2283.
20. Ma J, Mai HQ, Hong MH et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001; 19: 1350-1357.
21. Haeryama M, Sakata K, Shirato H et al. A prospective randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in advanced nasopharyngeal carcinoma. Cancer 2002; 94: 2217-2223.
22. Chan ATC. Head and neck cancer: Treatment of nasopharyngeal cancer. Ann Oncol 2005; 16: 265-268.
23. Rischin D, Corry J, Smith J et al. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation, J Clin Oncol 2002; 20: 1845-1852.
24. Oh JL, Vokes EE, Kies MS et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol 2003; 14: 564-569.
25. Chan AT, Ma B, Lo D et al. A phase II study of neoadjuvant taxol and carboplatin followed by concurrent cisplatn-radiotherapy in locoregionally advanced nasopharyngeal carcinoma with EBV DNA monitoring. J Clin Oncol 2004; 22: 1-8.
26. Pignon JP, Syz N, Posner M et al. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs 2004; 15: 331-340.
27. Wang TL, Tan YO. Cisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma. Ann Acad Med Singapore 1991; 20: 601-603.
28. Au E, Ang PT. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 1994; 5: 87-89.
29. Leong SS, Wee J, Tay MH et al. Pacitaxel, carboplatin and gemcitabine in metastatic nasopharyngeal carcinoma: A phase II trial using a triplet combination. Cancer 2005; 103: 569-575.
30. Yeo W, Leung TW, Chan AT et al. A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer 1998; 34: 2027-2031.
31. Tan EH, Khoo KS, Wee J et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 1999; 10: 235-237.
32. Airoldi M, Pedani F, Marchionatti S et al. Carboplatin plus taxol is an effective third line regimen in recurrent undifferentiated nasopharyngeal carcinoma. Tumori 2002; 88: 273-276.
33. Ma BB, Tannock IF, Pond GR et al. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 2002; 95: 2516-2523.
34. Ngan RK, Yiu HH, Lau WH et al. Combination gamcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol 2002; 13: 1252-1258.
35. Foo KF, Tan EH, Leong SS et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 2002; 13: 150-156.
36. Fandi A, Bachouchi M, Azli N et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 2000; 18: 1324-1330.
37. Chan AT, Hsu MM, Goh BC et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005; 23: 3568-3576.
38. Faivre S, Delbaldo C, Vera K. Safety, pharmacokinetic and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 112.